Patents by Inventor Lawrence Snyder
Lawrence Snyder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230203030Abstract: The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.Type: ApplicationFiled: September 13, 2022Publication date: June 29, 2023Inventors: Andrew P. Crew, Craig M. Crews, Xin Chen, Hanqing Dong, Caterina Ferraro, Yimin Qian, Kam Siu, Jing Wang, Meizhong Jin, Michael Berlin, Kurt Zimmermann, Lawrence Snyder
-
Publication number: 20220370416Abstract: Bifunctional compounds, which find utility as modulators of Kirsten ras sarcoma protein (KRas or KRAS), are described herein. In particular, the hetero-bifunctional compounds of the present disclosure contain on one end a moiety that binds to the Von Hippel-Lindau E3 ubiquitin ligase and on the other end a moiety which binds KRas, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The hetero-bifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aberrant regulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.Type: ApplicationFiled: April 6, 2021Publication date: November 24, 2022Inventors: Ling Chu, Craig M. Crews, Hanqing Dong, Keith R. Hornberger, Jesus Raul Medina, Lawrence Snyder, Jing Wang
-
Publication number: 20220323457Abstract: Bifunctional compounds, which find utility as modulators of B-cell lymphoma 6 protein (BCL6; target protein), are described herein. In particular, the bifunctional compounds of the present disclosure contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand that binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The bifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.Type: ApplicationFiled: October 16, 2020Publication date: October 13, 2022Inventors: Michael Berlin, Hanqing Dong, Dan Sherman, Lawrence Snyder, Jing Wang, Wei Zhang
-
Patent number: 11427548Abstract: The present disclosure relates to bifunctional compounds, which find utility to degrade (and inhibit) Androgen Receptor. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds Androgen Receptor such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of Androgen Receptor.Type: GrantFiled: October 17, 2019Date of Patent: August 30, 2022Assignee: ARVINAS OPERATIONS, INC.Inventors: Andrew P. Crew, Hanqing Dong, Jing Wang, Xin Chen, Yimin Qian, Kurt Zimmermann, Michael Berlin, Lawrence Snyder
-
Publication number: 20200392131Abstract: The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.Type: ApplicationFiled: June 18, 2020Publication date: December 17, 2020Inventors: Andrew P. Crew, Craig M. Crews, Xin Chen, Hanqing Dong, Caterina Ferraro, Yimin Qian, Kam Siu, Jing Wang, Meizhong Jin, Michael Berlin, Kurt Zimmermann, Lawrence Snyder
-
Patent number: 10730870Abstract: The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.Type: GrantFiled: March 18, 2016Date of Patent: August 4, 2020Assignees: ARVINAS OPERATIONS, INC., YALE UNIVERSITYInventors: Andrew P. Crew, Craig M. Crews, Xin Chen, Hanqing Dong, Caterina Ferraro, Yimin Qian, Kam Siu, Jing Wang, Meizhong Jin, Michael Berlin, Kurt Zimmermann, Lawrence Snyder
-
Publication number: 20200055825Abstract: The present disclosure relates to bifunctional compounds, which find utility to degrade (and inhibit) Androgen Receptor. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds Androgen Receptor such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of Androgen Receptor.Type: ApplicationFiled: October 17, 2019Publication date: February 20, 2020Inventors: Andrew P. Crew, Hanqing Dong, Jing Wang, Xin Chen, Yimin Qian, Kurt Zimmermann, Craig M. Crews, Michael Berlin, Lawrence Snyder
-
Patent number: 10330532Abstract: Examples of a method to use in an electronic device, an electronic device, and a machine-readable non-transitory storage medium are disclosed herein. An example of the machine-readable non-transitory storage medium includes instructions executable by a processor of an electronic device to generate a molecular signature tag based on molecular signature data representative of a determined molecular structure of an object scanned by a molecular detector of the electronic device and to embed the molecular signature tag in metadata of an image file based on a captured image of the object by a camera of the electronic device.Type: GrantFiled: November 10, 2014Date of Patent: June 25, 2019Assignee: Hewlett-Packard Development Company, L.P.Inventors: Greg Creager, Lawrence Snyders, Shaun Henry
-
Publication number: 20180346461Abstract: The present invention relates to bifunctional compounds, which find utility to degrade and (inhibit) Androgen Receptor. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds Androgen Receptor such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of Androgen Receptor.Type: ApplicationFiled: July 27, 2018Publication date: December 6, 2018Inventors: Andrew P. Crew, Hanqing Dong, Jing Wang, Xin Chen, Yimin Qian, Kurt Zimmermann, Craig M. Crews, Michael Berlin, Lawrence Snyder
-
Publication number: 20160272639Abstract: The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.Type: ApplicationFiled: March 18, 2016Publication date: September 22, 2016Inventors: Andrew P. Crew, Craig M. Crews, Xin Chen, Hanqing Dong, Caterina Ferraro, Yimin Qian, Kam Siu, Jing Wang, Meizhong Jin, Michael Berlin, Kurt Zimmermann, Lawrence Snyder
-
Publication number: 20160061536Abstract: A heat exchanger comprises a plurality of heat convection fins, first and second parallel U-shaped fluid tubes, and a fitting. Each of the first and second fluid tubes comprises a pair of leg portions and a U-turn portion that operatively connects the leg portions. The leg portions of the first fluid tube extend through at least some of the heat convection fins. The leg portions of the second fluid tube extend through at least some of the heat convection fins. The fitting comprises first and second female sockets. The first female socket is crimped to one of the leg portions of the first fluid tube. The second female socket is crimped to one of the leg portions of the second fluid tube. The fitting operatively connects the first and second fluid tubes.Type: ApplicationFiled: August 24, 2015Publication date: March 3, 2016Inventors: Bradley Arment, Sean Patrick Kelleher, Matthew Lawrence Snyder, Michael J. Duggan, Harold A. Liller
-
Publication number: 20060276511Abstract: Compounds having the structure of formula I are described. The compounds can inhibit hepatitis C virus (HCV) replication, and in particular can inhibit the function of the HCV NS5A protein.Type: ApplicationFiled: June 5, 2006Publication date: December 7, 2006Inventors: Michael Serrano-Wu, Makonen Belema, Lawrence Snyder, Nicholas Meanwell, Denis St. Laurent, Ramesh Kakarla, Van Nguyen, Yuping Qiu, Xuejie Yang, John Leet, Min Gao, Donald O'Boyle, Julie Lemm, Fukang Yang
-
Publication number: 20050096364Abstract: Compounds having the structure of formula I are described wherein R, R?, R1, R2, and R3 are as defined in the specification. The compounds can inhibit hepatitis C virus (HCV) replication, and in particular the function of the HCV NS5A protein.Type: ApplicationFiled: August 8, 2003Publication date: May 5, 2005Inventors: Jeffrey Romine, Scott Martin, Lawrence Snyder, Michael Serrano-Wu, Milind Deshpande, Darren Whitehouse, Julie Lemm, Donald O'Boyle, Min Gao, Richard Colonno
-
Publication number: 20050069522Abstract: Disclosed are combination pharmaceutical agents for the treatment of an HCV infection comprising a compound effective to inhibit the function of the HCV NS5A protein and another compound having anti-HCV activity. Compounds which can inhibit the function of the NS5A protein having the structure of formula I are described wherein R, R?, R1, R2, and R3 are as defined in the specification. The other compounds having anti-HCV activity are effective to inhibit the function of a target selected from the group consisting of HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase, HCV NS4B protein, HCV entry, HCV assembly, HCV egress, HCV NS5A protein, IMPDH and a nucleoside analog for the treatment of an HCV infection.Type: ApplicationFiled: August 8, 2003Publication date: March 31, 2005Inventors: Richard Colonno, Julie Lemm, Donald O'Boyle, Min Gao, Jeffrey Romine, Scott Martin, Lawrence Snyder, Michael Serrano-Wu, Milind Deshpande, Darren Whitehouse
-
Patent number: 5151900Abstract: A chaos router system for routing messages between connected nodes in a multicomputer or multiprocessor system is disclosed. In such a system, a message may be routed between nodes along a preferred channel so that it is closer to its destination or derouted between nodes along a random channel so that it is further from its destination. The chaos router system explicitly randomizes message selection during derouting. In an asynchronous multicomputer system, the router system keeps the overall system chaotic. In this manner, the system is probabilistically livelock free.Type: GrantFiled: June 14, 1991Date of Patent: September 29, 1992Assignee: Washington Research FoundationInventors: Lawrence Snyder, Smaragda Konstantinidou